» Articles » PMID: 17526992

Serum Carboxy-terminal Telopeptide of Type I Collagen (ICTP) Predicts Cardiac Events in Chronic Heart Failure Patients with Preserved Left Ventricular Systolic Function

Overview
Journal Circ J
Date 2007 May 29
PMID 17526992
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clinical markers to predict adverse outcome have not yet been established for patients with preserved left ventricular (LV) systolic function. The present study was designed to examine whether carboxy-terminal telopeptide of type I collagen (ICTP), a marker of collagen degradation, is useful for determining the prognosis of such patients.

Methods And Results: Serum levels of ICTP were measured at admission in 156 consecutive patients hospitalized for chronic heart failure (CHF). Patients were divided into 2 groups based on the LV ejection fraction (LVEF): reduced LV systolic function group (LVEF <50%, n=92) and preserved LV systolic function group (LVEF > or =50%, n=64). In preserved LV systolic function group, cardiac event-free rates were significantly lower in high ICTP group than in low ICTP group (p<0.001). The area under the receiver operating characteristic curve of ICTP in the preserved LV systolic function group was markedly larger than that in the reduced LV systolic function group. Cox multivariate analysis also revealed that ICTP was an independent predictor of cardiac events in the preserved LV systolic function group.

Conclusion: Serum ICTP level is highly reliable for risk stratifying CHF patients with preserved LV systolic function.

Citing Articles

The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients.

Pane C, Trinchillo A, Salzano A, Marsili A, Puorro G, Cittadini A Cerebellum. 2022; 22(5):1034-1038.

PMID: 36066808 DOI: 10.1007/s12311-022-01475-4.


Extracellular Matrix in Heart Disease: Focus on Circulating Collagen Type I and III Derived Peptides as Biomarkers of Myocardial Fibrosis and Their Potential in the Prognosis of Heart Failure: A Concise Review.

Nikolov A, Popovski N Metabolites. 2022; 12(4).

PMID: 35448484 PMC: 9025448. DOI: 10.3390/metabo12040297.


Exploring the Correlation Between Fibrosis Biomarkers and Clinical Disease Severity in PLN p.Arg14del Patients.

van der Voorn S, Bourfiss M, Te Riele A, Taha K, Vos M, de Brouwer R Front Cardiovasc Med. 2022; 8:802998.

PMID: 35097021 PMC: 8793805. DOI: 10.3389/fcvm.2021.802998.


Roles of Biomarkers in Myocardial Fibrosis.

Ding Y, Wang Y, Zhang W, Jia Q, Wang X, Li Y Aging Dis. 2020; 11(5):1157-1174.

PMID: 33014530 PMC: 7505259. DOI: 10.14336/AD.2020.0604.


Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review.

Berezin A, Berezin A Diabetes Ther. 2020; 11(6):1271-1291.

PMID: 32430864 PMC: 7261294. DOI: 10.1007/s13300-020-00835-9.